MA44384A - Formulation d'amidon de pois d'acide polyinosinique-polycytidylique (poly(i:c)) pour la prévention et/ou le traitement d'infections des voies respiratoires supérieures - Google Patents

Formulation d'amidon de pois d'acide polyinosinique-polycytidylique (poly(i:c)) pour la prévention et/ou le traitement d'infections des voies respiratoires supérieures

Info

Publication number
MA44384A
MA44384A MA044384A MA44384A MA44384A MA 44384 A MA44384 A MA 44384A MA 044384 A MA044384 A MA 044384A MA 44384 A MA44384 A MA 44384A MA 44384 A MA44384 A MA 44384A
Authority
MA
Morocco
Prior art keywords
polyinosinic
poly
prevention
treatment
respiratory tract
Prior art date
Application number
MA044384A
Other languages
English (en)
French (fr)
Inventor
Jurgen Mensch
Dijck Alex Henri Van
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA44384A publication Critical patent/MA44384A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/02Starch; Degradation products thereof, e.g. dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA044384A 2015-05-11 2016-05-10 Formulation d'amidon de pois d'acide polyinosinique-polycytidylique (poly(i:c)) pour la prévention et/ou le traitement d'infections des voies respiratoires supérieures MA44384A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15167129 2015-05-11

Publications (1)

Publication Number Publication Date
MA44384A true MA44384A (fr) 2019-01-23

Family

ID=53174864

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044384A MA44384A (fr) 2015-05-11 2016-05-10 Formulation d'amidon de pois d'acide polyinosinique-polycytidylique (poly(i:c)) pour la prévention et/ou le traitement d'infections des voies respiratoires supérieures

Country Status (12)

Country Link
US (1) US20180353533A1 (enExample)
EP (1) EP3294268A1 (enExample)
JP (1) JP2018515530A (enExample)
KR (1) KR20180004233A (enExample)
CN (1) CN107820423A (enExample)
AU (1) AU2016259869A1 (enExample)
CA (1) CA2983659A1 (enExample)
HK (1) HK1251926A1 (enExample)
MA (1) MA44384A (enExample)
RU (1) RU2017142710A (enExample)
TW (1) TW201705963A (enExample)
WO (1) WO2016181226A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112423771B (zh) * 2018-07-20 2023-05-09 株式会社资生堂 病毒灭活剂
CU20200110A7 (es) * 2020-12-23 2022-08-09 Ct Ingenieria Genetica Biotecnologia Péptidos para el tratamiento de infecciones respiratorias de origen viral
KR102439760B1 (ko) 2021-03-09 2022-09-02 주식회사 오라팜 상기도 감염균 질환 예방 및 치료를 위한 조성물
KR102451861B1 (ko) 2021-03-09 2022-10-07 주식회사 오라팜 급성 호흡기 바이러스 및 로타바이러스 감염 질환 예방 및 치료를 위한 조성물
CN114917242A (zh) * 2022-05-31 2022-08-19 复旦大学附属中山医院 合成双链rna类似物经滴鼻预防呼吸道传播病毒的应用及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
CN101229378A (zh) * 2005-05-05 2008-07-30 国家淀粉及化学投资控股公司 用于送递活性剂的组合物
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
CN101757018A (zh) * 2008-12-24 2010-06-30 天津瑞普生物技术股份有限公司 一种用于畜禽的聚肌胞干粉及其制备方法
CN102988303A (zh) * 2011-09-15 2013-03-27 天津泽世德生物医药有限公司 一种多聚肌苷酸多聚胞苷酸冻干粉针的制备方法
US9682096B2 (en) * 2012-05-02 2017-06-20 Janssen R & D Ireland Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
TWI643082B (zh) * 2013-09-03 2018-12-01 美商新思科技股份有限公司 一種佈線出一解決路徑之方法及系統
WO2015067632A1 (en) * 2013-11-06 2015-05-14 Janssen Sciences Ireland Uc Polylnosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Also Published As

Publication number Publication date
JP2018515530A (ja) 2018-06-14
EP3294268A1 (en) 2018-03-21
CA2983659A1 (en) 2016-11-17
TW201705963A (zh) 2017-02-16
CN107820423A (zh) 2018-03-20
RU2017142710A (ru) 2019-06-11
US20180353533A1 (en) 2018-12-13
WO2016181226A1 (en) 2016-11-17
HK1251926A1 (zh) 2019-05-03
KR20180004233A (ko) 2018-01-10
AU2016259869A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
FR22C1063I2 (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3370748A4 (en) THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND / OR PREVENTION OF FOOD ALLERGY
EP3600281A4 (en) COMBINATION THERAPY FOR TREATING OR PREVENTING TUMORS
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
FR3011467B1 (fr) Composes et compositions comprenant de tels composes pour la prevention ou le traitement des dyslipidemies
MA44384A (fr) Formulation d'amidon de pois d'acide polyinosinique-polycytidylique (poly(i:c)) pour la prévention et/ou le traitement d'infections des voies respiratoires supérieures
EP3341001A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT AND PROPHYLAXIS OF DARMINFECTION AND IGNITION
EP3448421A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING SURGICAL ADHESIVES
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3344325A4 (en) LOCAL ADMINISTRATION OF MEDICAMENTS FOR THE TREATMENT OF ASTHMA
EP3347096A4 (en) STICK OXIDE INHALATION THERAPY FOR SMALL CHILDREN WITH BRONCHIOLITIS
EP3766497A4 (en) Drug for treating cough
EP3324944A4 (en) INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP3716966A4 (en) ALPHA-KETO ACID COMPOSITIONS FOR THE TREATMENT OF HYPOALBUMINEMIA
MA42985A (fr) Traitement de troubles liés à l'acide biliaire
EP3430400A4 (en) DOSAGE PLANS FOR THE TREATMENT OF FUNGI INFECTIONS
EP3632431A4 (en) Agent for preventing or treating brain atrophy
EP3758716A4 (en) Formulations treating acid reflux comprising sodium alginate
EP3419981A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
EP3329929A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DRY EYES
EP3827831A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
EP3398614A4 (en) AGENTS FOR PREVENTION AND / OR TREATMENT OF MORBUS ALZHEIMER
EP3340947A4 (en) DEVICE FOR TREATING MEDIAL TIBIAL STRESS SYNDROME AND OTHER STATE OF CONDITIONS